Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | IDH2 |
| Variant | V305M |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | IDH2 V305M does not lie within any known functional domains of the Idh2 protein (UniProt.org). V305M has been identified in the scientific literature (PMID: 34994649), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Sep 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
IDH2 mutant IDH2 V305M |
| Transcript | NM_002168.4 |
| gDNA | chr15:g.90087166C>T |
| cDNA | c.913G>A |
| Protein | p.V305M |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002168.3 | chr15:g.90087166C>T | c.913G>A | p.V305M | RefSeq | GRCh38/hg38 |
| NM_002168.4 | chr15:g.90087166C>T | c.913G>A | p.V305M | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH2 V305M | malignant epithelioid hemangioendothelioma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a Phase II trial (OLAPCO), Lynparza (olaparib) treatment resulted in stable disease lasting 11 months in a patient with pulmonary epithelioid hemangioendothelioma harboring IDH2 V305M (PMID: 34994649, NCT02576444). | 34994649 |